Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trial
Tomoyoshi Tamura, Masaru Suzuki, Koichiro Homma, Motoaki Sano, Ryoji Iizuka, Hiromichi Narimiya, Ryosuke Tsuruta, Kotaro Kaneda, Motoki Fujita, Junichi Sasaki, Osamu Akasaka, Keisuke Sawai, Makiko Nozaki, Hiroshi Imai, Ken Ishikura, Kaoru Ikejiri, Yasuyuki Kakihana, Shuhei Niiyama, Takahiro Futatsuki, Masahiro Honda, Yasuhiro Ikeda, Hideo Oka, Hideaki Yoshihara, Hirokazu Onishi, Susumu Yamashita, Koki Shimizu, Toshihiro Sakurai, Shu Yamada, Hiroshi Fukami, Nobuaki Shime, Kei Suzuki, Yasuhiro Kuroda, Kenya Kawakita, Akio Kimura, Tatsuki Uemura, Kiyotsugu Takuma, Kunio Kanao, Youichi Yanagawa, Ikuto Takeuchi
Abstract
Background: would improve outcomes after out-of-hospital CA (OHCA). Methods: or oxygen (control) for 18 h. The primary outcome was the proportion of patients with a 90-day Cerebral Performance Category (CPC) of 1 or 2 assessed in a full-analysis set. Secondary outcomes included the 90-day score on a modified Rankin scale (mRS) and survival. HYBRID II was registered with the University Hospital Medical Information Network (registration number: UMIN000019820) and re-registered with the Japan Registry for Clinical Trials (registration number: jRCTs031180352). Findings: and control groups, respectively (P = 0.02). Interpretation: inhalation may increase 90-day survival without neurological deficits. Funding: Taiyo Nippon Sanso Corporation. Translation: For the Japanese translation of the abstract see Supplementary Materials section.